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Development of a malignant germ cell tumor, i.e., germ cell cancer (GCC) in
individuals with disorders of sex development (DSD) depends on a number
of (epi-)genetic factors related to early gonadal- and germ cell development,
possibly related to genetic susceptibility. Fetal development of germ cells is
orchestrated by strict processes involving specification, migration and the
development of a proper gonadal niche. In this review we will discuss the
early (epi-)genetic events in normal and aberrant germ cell and gonadal
development. Focus will be on the formation of the precursor lesions of
GCC in individuals who have DSD. In our view, expression of the different
embryonic markers in, and epigenetic profile of the precursor lesions reflects
the developmental stage in which these cells are blocked in their maturation.
Therefore, these are not a primary pathogenetic driving force. Progression
later in life towards a full blown cancer likely depends on additional factors
such as a changed endocrine environment in a susceptible individual.
Genetic susceptibility is, as evidenced by the presence of specific risk
genetic variants (SNPs) in patients with a testicular GCC, related to genes
involved in early germ cell and gonadal development.
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Establishment of sex is a critical and crucial part of
mammalian development providing the fundamental
structure for maintenance of the species, as well as
continued generation of genetic diversity. In mammals
this process has two sequential stages, being sex
determination followed by sex differentiation. Mam-
malian sex determination is, with a few exceptions,
driven by the presence of a specific combination of
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sex-chromosomes, either XY or XX. This leads to
the development of either a male- or female- gonad
originating from an initially undifferentiated bipotential
structure. Presence of the Y chromosome, more specif-
ically expression of the SRY (sex determining region
on Y) gene initiates testis development, while absence
of a functional Y chromosome will in-principle lead
to the development of an ovary. During the process
of sex differentiation, secretion of local and hormonal
factors by the fully formed testis or ovary, results in
the formation of the internal and external genitalia. A
disturbance in gonadal development as well as in its
subsequent functionality, can lead to disorders of sex
development (DSD), defined as congenital conditions
in which development of chromosomal, gonadal or
anatomical sex is atypical. Some of these conditions are
associated with an increased risk for a germ cell cancer
(GCC). Here we discuss the (epi)genetic processes
involved in normal early gonadal and (embryonic) germ
cell development, and focus on the pathogenesis of the
precursor lesions of GCC in the context of DSD.
Normal germ cell development
Primordial germ cells (PGCs) are the precursors of
gametogenesis in later life. In the mouse these cells
develop in the proximal epiblast, and become detectable
at embryonic day E6.5. Specification of PGCs takes place
in response to bone morphogenetic protein 4 (BMP)
signaling at approximately E6.0 (1). Cells expressing
BLIMP1 and PRDM14, induced by BMP signaling,
form a cluster of about 40 alkaline phosphatase (AP)
positive PGCs at E7.25 (2–4). At E7.5 these PGCs
migrate to the developing hindgut and continue at E9.5
through the mesentery and colonize the genital ridges
at E10.5-12.5 (5, 6). Once arrived in the genital ridge
(i.e. the undifferentiated gonad), PGCs are referred to as
gonocytes. During this time, both in the male and female,
extensive epigenetic reprogramming takes place.
Germ cell epigenetics before and after gonadal
differentiation
The most notable epigenetic event taking place at
these early developmental stages is genome-wide DNA
demethylation, which is completed at E13.5 (7, 8).
As a consequence of this process, parental imprints
are erased, and the silenced X chromosome is reac-
tivated in PGCs of female (XX) mouse embryos (9,
10). From E12.5 onwards differentiation of the mouse
embryo is sex-specific (11). After PGC reprogram-
ming, establishment of germ cell methylation marks
happens in a sex-specific manner, resulting in sperm-
and oocyte-specific methylation patterns (9). In males,
re-methylation initiates as early as E14.5 in G1 arrested
prospermatogonia (12), and is fully established at birth
(days 19–21). The methylation patterns are maintained
throughout many mitotic divisions before the cells enter
meiosis (13). In females re-methylation of the gametes
starts at birth during the oocyte growth phase at which
time they are arrested in prophase of meiosis I (12).
Besides these epigenetic events, multiple signaling path-
ways are activated in PGCs/gonocytes.
Signaling pathways in primordial germ cells
It is known that the KIT-KITLG (stem cell factor,
SCF) pathway plays an important role in the migration,
proliferation and survival of mouse PGCs (14, 15).
Recently, a number of additional relevant pathways in
embryonic germ cells have been identified. It has been
shown that mouse PGCs express the estrogen receptor α
and ß at E11.5–12.5, and exposure to estrogens leads to
phosphorylation of AKT, ERK and SRC, which regulate
(de)differentiation of mouse germ cells (16, 17). Excess
exposure to estrogens during the in vitro growth of
mouse genital ridges, results in upregulation of KITLG
and activation of the KIT pathway via AKT/PTEN,
which in turn leads to proliferation of PGCs (18). The
window of sensitivity for AKT signaling is restricted,
as it is absent in germ cells in mitotic arrest and in
the beginning of meiosis (17). Knock-out of PTEN in
human embryonic stem cells (ES), resulted in increased
cell survival and proliferation, and these cells had less
differentiation capacity due to retained OCT3/4 and
NANOG expression levels (19). Both PTEN and P53
independently repress expression of Nanog in mouse
spermatogonial stem cells. Although these studies give
more insight in the signaling pathways involved in the
development of PGCs/gonocytes, their relevance for
human germ cell development remains to be determined.
Early gonadal differentiation, fetal testis and ovary
development.
Differentiation of the early gonad, and development
of the fetal testis and ovary are presented elsewhere
in this issue, and will only be discussed briefly here.
In the early stages of mammalian embryonic develop-
ment the undifferentiated gonads are bipotential. For-
mation of the early undifferentiated gonad is influenced
by a number of genes, including steroidogenic factor-1
(SF1/NR5A1), Wilms’ tumor-1 (WT1), and chromobox
homolog-2 (CBX2) (20–22). Studies in mice have shown
that these genes play an important role in the devel-
oping gonads, and moreover, all have been associated
with DSD (see below). Differentiation of the bipotential
gonad into a testis begins with the specification of Ser-
toli cells, triggered by expression of the Y-linked SRY ,
and subsequent SOX9 (SRY-related HMG-box, gene 9)
(23–25). Sertoli cells subsequently coordinate all aspects
of testis differentiation and function (26). Anti-Müllerian
hormone (AMH), and chemotactic signals produced by
the early Sertoli cells causes regression of the Mülle-
rian ducts, and ensure correct cell migration and testis
cord formation (26, 27). The appearing fetal Leydig cells
start producing testosterone (T) and insulin-like factor
3 (INSL3) inducing masculinization of the fetus (28,
29). PGCs/goncytes colonizing the early testis continue
to proliferate until 17–18 weeks GA, at which time
293
Hersmus et al.
they start to mature into pre-spermatogonia, and start
migrating towards the basement membrane. During this
time they will lose expression of embryonic markers like
POU5F1, NANOG, AP, Ap2gamma and c-KIT, and will
enhance expression of amongst others TSPY and VASA
(DDX4) (30–33). Occasionally, a few PGCs/gonocytes,
expressing embryonic markers, can still be found in the
postnatal testis until 6–12 months of age (31). Until
recently ovarian development was thought to be the result
of a passive or default pathway, i.e. occurring in the
absence of SRY expression. However, in recent years, it
has been shown that ovarian development requires tightly
regulated signaling pathways involving WNT family
member 4 (WNT4), Forkhead Box L2 (FOXL2), Catenin
beta-1 (CTNNB1) and R-spondin 1 (RSPO1) (34–37).
In the fetal ovary the germ cells are called oogonia, they
proliferate and their numbers increase to around 7 × 105
oocytes at birth. During this time embryonic markers like
POU5F1 and NANOG are downregulated (38). Prolif-
eration, meiotic entry and oocyte formation depend on
the interaction with primarily granulosa cells, for which
FOXL2 is essential (39). The primordial follicle consists
of an individual oocyte, arrested in meiosis I, and sur-
rounded by a layer of pre-granulosa cells (40).
It has become clear that in order to properly develop,
the testis and ovary need to suppress the opposing
pathways. In the XY gonad WNT4 is suppressed
by FGF9 (fibroblast growth factor-9), and loss of
Wnt4 in XX gonads leads to upregulation of Fgf9 and
Sox9 (41). Moreover, it has been shown that Ctnnb1,
Map3k1 (member of the mitogen-activated protein
kinase (MAPK) pathway) and NR5A1 also play a role
(35, 42, 43). Interestingly, even in adulthood testes
and ovaries need to suppress activation of opposing
pathways (44, 45).
A graphic overview of normal germ cell – and gonadal
development; indicating timing, genes involved, and
expression of germ cell markers is shown in Fig. 1.
Disturbed germ cell development
A disturbance in gonadal development as described
above, can lead to DSD, which are categorized into three
main groups based on karyotype: 46,XY DSD, 46,XX
DSD, and chromosomal DSD. Each main group further
consists of a spectrum of genetic diseases, hormonal
disorders and syndromic forms. Defects in several genes
have been shown to result in gonadal malformation and
DSD, some of which will be discussed below. DSD
patients with Y chromosomal material in their karyotype
have the greatest risk of developing the GCC precursor
lesion, with a high potential to progress to GCC, see
below. We have developed a comprehensive and inter-
active overview of normal sex development and DSD,
publically available (http://www.erasmusmc.nl/47463/
51019/4500578/Animation).
Genetic factors involved in gonadal maldevelopment in DSD
Mutations in the genes involved in formation of the
undifferentiated gonad (NR5A1, WT1 and CBX2) have
indifferent bipotential gonad
epiblast
NR5A1, WT1, CBX2
XY XX
SRY
SOX9
NR5A1
FGF9
WNT4
RSPO1
FOXL2
erased im
printing
testis ovary
male female
AMH
T
INSL3
DHT
absence
AMH
T
chromosomal
sex
gonadal
sex
phenotypic
sex
GA
6-8
12-14
birth
1 year
germ cell
markers
expression of P
O
U
5F
1 (O
C
T
3/4), A
P
, K
IT
primordial germ cell/gonocytesupportive cells (pre-)Sertoli or granulosa))
pre-spermatogonium oocyte forming seminiferous tubule
m
ig
ra
tio
n,
 
pr
ol
ife
ra
tio
n
Fig. 1. Schematic representation of the earliest steps in human male
and female development. Early in development in both chromosomal
males and females the indifferent bipotential gonads are formed under
the influence of NR5A1, WT1 and CBX2. In the XY embryo, expression
of SRY initiates upregulation of SOX9, inducing a signaling cascade
involving FGF9 and NR5A1 that leads to the formation of pre-Sertoli
cells. These cells will further orchestrate the development of a functional
testis, which in turn will, through the action of anti-Müllerian hormone
(AMH), testosterone (T), insulin-like 3 (INSL3), and dihydrotestosterone
(DHT), direct the differentiation of the male internal and external
genitalia. In the XX embryo, the absence of functional SRY directs the
fate of the bipotential gonad towards the ovarian lineage. Instead of
one master gene, several proteins act in parallel in female development.
The absence of AMH and T leads to the differentiation of the female
internal and external genitalia. The primordial germ cells (PGCs) arise
early in development in the proximal epiblast, and migrate towards
the genital ridges. During this time the PGCs will undergo extensive
epigenetic changes, and by the time they arrive in the gonadal ridges,
genomic imprinting is completely erased. A male or female specific
pattern of imprinting will be established depending on the presence of
a testicular or ovarian environment. In the testis the PGCs/gonocytes
associated with pre-Sertoli cells, go into mitotic arrest and differentiate
into pre-spermatogonia. In the ovary, gonocytes will differentiate into
oocytes. During this process both in the male and female, the germ cells
will lose expression of the embryonic markers POU5F1, AP, and KIT,
which should be absent after the first year of life. GA: gestational age in
weeks. See text for further details.
been found in patients with DSD. Human NR5A1 muta-
tions have been associated with adrenal failure, primary
ovarian insufficiency, and 46,XY complete or partial
gonadal dysgenesis (a complete or partial lack of tes-
ticular development resulting in a female or ambiguous
phenotype), and even 46,XX (ovo)testicular DSD (43,
46, 47). Specific WT1 mutations are known to cause
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Denys–Drash and Frasier syndrome, characterized by
an increased risk for Wilms’ tumor and renal failure,
respectively, and 46,XY partial or complete gonadal dys-
genesis (48, 49). Disruption of Cbx2 in mice leads to
defects in adrenal and splenic development, but also
to varying degrees of 46,XY sex reversal, most likely
related to reduced expression of Sry (50). In humans
a loss-of-function mutation in a patient with 46,XY
gonadal dysgenesis has been described (51). As men-
tioned earlier, testicular development starts with SRY-
and subsequently SOX9 expression. Eighty percent of
46,XX testicular DSD cases can be attributed to translo-
cation of SRY to one of the X chromosomes; and
15–20% of 46,XY gonadal dysgenesis are caused by
an inactivating mutation of SRY (52–54). Mutations in
SRY have also been described in some cases with a
mosaic sex chromosome constitution, indicating a pos-
sible role for SRY in the abnormal gonadal develop-
ment in these patients (55, 56). Interestingly, a family has
been described in which two sisters with 46,XY gonadal
dysgenesis had an identical frameshift mutation in SRY ,
which was absent in the brother, but present in the father
in a mosaic constitution (57). Moreover, Shahid et al.,
describe a family in which the father of a DSD patient
with a mosaic 45,X/46,XY karyotype displayed signs
of testicular dysgenesis syndrome (TDS), and molecu-
lar analysis revealed the same deletion in the HMG-box
of SRY in both (58). NR0B1 (DAX1) encodes an orphan
nuclear receptor; and gene duplications resulting in sup-
pression of the SRY pathway cause 46,XY DSD (59).
Mutations in SOX9 have been identified in individu-
als with campomelic dysplasia and 46,XY DSD, and
duplications of chromosome 17q, including SOX9 were
found in 46,XX testicular DSD cases (60–62). Next to
the aforementioned genes, missense mutations in desert
hedgehog (DHH), a signaling molecule involved in reg-
ulation of morphogenesis, cause 46,XY complete or par-
tial gonadal dysgenesis (63). Loss of the 9p region which
includes DMRT1, a transcription factor expressed in the
testis of humans and mice, is associated with gonadal
dysgenesis and 46,XY DSD (64). Besides these, muta-
tions in MAP3K1, have been found in several cases of
46,XY DSD (65). Mutations in human GATA4, a mem-
ber of the GATA family of transcription factors, have first
been associated with congenital heart defects (CHD).
However, several cases of 46,XY DSD, sometimes in
combination with CHD have been described in fami-
lies with mutations or copy number variations (CNVs)
in GATA4, or its co-factor ZFPM2 (zinc finger protein,
FOG family member 2) (66–68). Lastly, in an individ-
ual with 46,XY gonadal dysgenesis a deletion spanning
multiple exons in the WWOX gene was found (69).
Recently, it has been shown that ovarian development
involves tightly regulated pathways, and mutations in the
genes involved can lead to DSD. Specifically, homozy-
gous null mutations in WNT4 have been shown to cause
46,XX DSD (70), and heterozygous loss-of-function
mutations have been described in rare cases of 46,XX
women with Mayer–Rokitansky–Küster–Hauser
(MRKH) and mild virilization (71, 72). Loss-of-function
mutations of RSPO1, a member of the R-spondin family,
Table 1. Genes involved in disorders of sex development
Gene
Disorder of sex
development (DSD) References
CBX2 46,XY gonadal dysgenesis (51)
DHH 46,XY complete and partial
gonadal dysgenesis
(63)
DMRT1 46,XY DSD (64)
GATA4 46,XY DSD (66, 67)
MAP3K1 46,XY DSD (42, 65)
NR0B1 (DAX1) 46,XY DSD (59)
NR5A1 (SF1) 46,XY gonadal dysgenesis;
46,XX ovotesticular DSD
(43, 46, 47)
RSPO1 46,XX DSD (73, 74)
SOX9 46,XY DSD; 46,XX testicular
DSD
(60–62)
SRY 46,XY gonadal dysgenesis;
chromosomal DSD
(52–58)
WNT4 46,XX DSD (70–72)
WT1 46,XY DSD, Denys–Drash and
Frasier syndrome
(48, 49)
WWOX 46,XY gonadal dysgenesis (69)
ZFPM2 46,XY DSD (68)
are associated with SRY-negative 46,XX DSD (73, 74).
Next to WNT4 and RSPO1, loss-of-function mutations
in the gene encoding the transcription factor FOXL2 are
associated with BPES (blepharimosis ptosis epicanthus
inversus syndrome) with or without ovarian dysgenesis
(75). An overview of the genes involved can be found in
Table 1, and Fig. 1.
Although the number of genes implicated in DSD is
growing, a molecular diagnosis cannot be made in about
75% of DSD individuals. New technologies like next
generation sequencing will likely improve on this, and
will uncover multigenic cases (76).
Next to these genetic factors, environmental factors
play a role in gonadal and genital development. These
can be due to placental insufficiency, possibly related
to intra-uterine environment and endocrine disruptors,
and should be considered as contributing factors to
DSD-related conditions such as cryptorchidism and
hypospadias (77, 78).
Disturbed microenvironment for embryonic germ cells
Gonadal maldevelopment as described above, or lack
of hormone production or action, results in a disturbed
nourishing microenvironment for the PGCs/gonocytes.
In these conditions, supportive Sertoli/granulosa cells
and/or Leydig/theca cells cannot provide a proper niche
for the germ cells, causing a delay or block in the neces-
sary maturational steps for full functionality as described
above. This can ultimately result in infertility or even
GCC, and the combination of both. Immature germ cells
can be identified by the expression of the aforemen-
tioned embryonic markers (POU5F1, NANOG, etc.) at a
stage beyond their normal expression window. The pre-
cursor lesions of GCC are the germ cell neoplasia in situ
(GCNIS, formerly termed carcinoma in situ – CIS) or
gonadoblastoma (GB), as discussed below.
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Fig. 2. Immunohistochemical staining pattern of GB and GCNIS. (a–f) Presence of GB and GCNIS in a single DSD gonad. (a) Representative
hematoxylin and eosin staining. On the left side of the image the GB lesion (indicated with *), embryonic germ cells mixed with granulosa-like
supportive cells, can be seen. On the right of the image GCNIS (indicated with #), is present, with embryonic germ cells on the basal lamina associated
with Sertoli cells. Both GB and GCNIS cells stain positive for (b) POU5F1 (brown staining), (c) TSPY (red staining), and (d) KITLG (brown staining).
(e, f) The supportive cells in the GCNIS lesion are SOX9 positive (brown staining), and are negative for FOXL2. In the GB lesion the supportive cells
stain positive for FOXL2 (brown staining) and are negative for SOX9. Adapted from (104). (g) As evidenced in the GB lesion found in another DSD
patient, next to this FOXL2 only staining pattern, also the presence of both markers, sometimes even within one cell (indicated by the arrow), is observed
(FOXL2: brown staining, SOX9: blue staining). Magnification: (a–d) ×200, (e–g) ×400. Slides (b–g) are counterstained with hematoxylin.
Germ cell cancer
The focus of this review being on the earliest steps
in the pathogenesis of GCC, invasive GCC will only
be discussed briefly. If untreated, the precursor lesion
GCNIS will progress into an invasive GCC in an esti-
mated 70% of cases, whereas around 50% of cases with
GB will progress to dysgerminoma/seminoma (79–81).
There are, in principle, five types of germ cell tumors,
but only the type II, the seminomas/dysgerminomas
and non-seminomas, are relevant in the context of
DSD. In the testis, these cancers are now referred to
as GCNIS-related germ cell tumors according to the
latest WHO classification (82). Diagnostic markers
for the invasive components can in fact be predicted
based on the expected expression pattern, and knowl-
edge of the precursor lesions either, GCNIS or GB.
These are POU5F1 for both seminomas and embry-
onal carcinoma, independent of stage of the disease
at clinical presentation and anatomical localization. In
addition, SOX17 is present in seminomas and SOX2
in embryonal carcinomas, allowing a straightforward
way of diagnosing these components (83). Of interest
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Fig. 3. Immunohistochemical staining of pre-GCNIS present in the testis of a 12-year-old presenting with severe hypospadias and cryptorchidism. (a)
Representative hematoxylin and eosin staining of the area containing pre-GCNIS cells. (b) Germ cells, both pre-malignant and with maturation delay,
stain positive for POU5F1 (brown staining). (c) In the staining for KITLG only pre-GCNIS cells stain positive (brown staining). (d) Double staining
for POU5F1 (brown staining) and TSPY (blue staining). Note that the majority of cells are positive for either TSPY or POU5F1, and only a few cells
show staining for both (arrowheads). Magnification: (a) ×200, (b–d) ×630. (b and c) are counterstained with hematoxylin.
is that the switch from SOX2 in embryonic stem cells
(ES) towards SOX17 in PGCs has indeed recently been
proven to be the driving force in the differentiation
of PGCs from ES (83, 84). There seems to be a reg-
ulatory mechanism in which POU5F1 switches from
SOX partner thereby targeting specific loci to deter-
mine cell fate (85). Based on actual data, there is no
indication that genomic anomalies affecting these loci
are driving cancer development, it just are persisting
embryonic signaling programs. Interestingly, a defined
set of micro-RNAs (miRs) show a characteristic pattern
of expression in GCC (86). A functional role has been
identified for miR-371–373, specifically the inhibition
of LATS2, a downstream target of the P53 pathway (87),
providing an explanation for the unusual presence of
wild type P53 in GCC. The miR cluster 371–373 is
normally only expressed in the embryonic germ/stem
cells during embryogenesis, indicating that the origin
of GCC lies in early embryonic development (88).
Recently, the elevated presence of this cluster of miRs in
serum from testicular GCC patients has been described
(89–91). However, they cannot detect patients with
GCNIS only (92). A further breakthrough in under-
standing GCC pathogenesis came from genome-wide
association studies (GWAS) in which a selected number
of high risk single nucleotide polymorphisms (SNPs)
were identified (93–97). None of the GWAS showed a
difference in effect in seminoma vs non-seminoma cases,
despite sufficient sample size, supporting the presence of
common oncogenic pathways in both groups. Interest-
ingly, one SNP (rs4590952) residing in the P53 binding
site of KITLG, thereby modulating its expression, is
located in the same linkage disequilibrium block as
the SNP found by Kanetsky et al. in 2009. (93, 98).
Studying promoter methylation of several of the
associated genes found in the GWAS showed that
increased promoter methylation of PDE11A, SPRY4,
and BAK1, and decreased promoter methylation of
KITLGwere significantly associated with familial testic-
ular GCC risk (99). Another intriguing finding pointing
towards susceptibility, is the presence of heterozygous
germline mutations in LRCC50 in familial seminoma
cases. Expression of the wild type allele is at least
partially lost in these familial seminomas (100). These
findings open up possible novel ways for the diagnosis
and follow-up of GCC patients and for genetic sus-
ceptibility screening in GCC risk populations such as
DSD (101).
Germ cell cancer precursor lesions
The precursor lesion of GCC in the testis is GCNIS (82,
102). In DSD, GB can also be found in the dysgenetic
gonad, and sometimes both precursor lesions are present
within the same gonad (Fig. 2) (79, 103). Presence of
GB, possibly combined with GCNIS, found in a scro-
tal testis, always indicates an underlying DSD condition
(104). GCNIS and GB can be distinguished by the char-
acteristics of the supportive cells, being exclusively Ser-
toli cells (SOX9 positive) in GCNIS, and granulosa cells
(FOXL2 positive) or a combination of both cell types, in
GB (Fig. 2) (105). The level of testicular development
(testicularization), as evidenced by overall morphology
and SOX9 and FOXL2 expression determines the type
of precursor. Malignant transformation of the germ cells
requires, next to other factors described below, a suscep-
tible environment. If the gonads have fully developed in
either the female (ovary) or male (testis) direction, risk
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Fig. 4. Pathobiology of germ cell cancer in DSD. Individuals with DSD
can have a disturbed gonadal development in which the function of the
supportive Sertoli/granulosa cells is impaired. Germ cells residing in
this disturbed microenvironment can undergo apoptosis, or be arrested
in their development, the latter leading to infertility, or alternatively,
these cells can give rise to the precursor lesions. Prolonged expression of
POU5F1, KITLG and increased TSPY expression enhances the chances
of survival of these germ cells. Formation of gonadoblastoma (GB) or
germ cell neoplasia in situ (GCNIS) depends on the level of testicu-
lar development (testicularization), as evidenced by the expression of
FOXL2 and SOX9 in the supportive cells. The expressed embryonic
markers and epigenetic profile of GB and GCNIS reflect the develop-
mental stage at which these cells are blocked, and are most likely not
a driving mechanism. Development of these precursors later in life into
germ cell cancer depends on a changed endocrine milieu in a susceptible
individual. This susceptibility might depend on the presence of the risk
SNPs (single nucleotide polymorphisms) identified in the genome-wide
association studies.
for malignant transformation of the germ cells is low, as
is the case in ovotesticular DSD where development of a
precursor lesion is rarely seen.
GCNIS cells resemble PGCs/gonocytes both pheno-
typically and ultrastructural; they show the same gene
and miRNA expression profiles, have a similar epige-
netic status, and express the same proteins, such as
POU5F1, AP, c-KIT and KITLG (31, 106–113). The
germ cell component of GB and GCNIS are identi-
cal, both morphologically as well as with regard to
protein expression, providing further evidence that the
cell-of-origin for both GCNIS and GB is a blocked
PGC/gonocyte (114, 115). There are a number of diag-
nostic markers for both precursor lesions, including, his-
torically AP and c-KIT. It must be noted that routine use
of c-KIT detection nowadays, given the sensitivity and
automated detection methods, can lead to over-diagnosis
(116). Interestingly, in ovarian GCCwithout any signs of
DSD a high frequency of c-KIT activating mutations (up
to 50%) was found (117), while individuals with DSD
with a specific part of the Y chromosome present, the
so-called GBY region (118), show expression of TSPY
(testis specific protein on the Y chromosome, see below),
suggesting that the c-KIT pathway is bypassed by the
presence of TSPY (117, 119). One of the most spe-
cific marker for both GCNIS and GB to date is POU5F1
(Fig. 2) (110). Prolonged POU5F1 expression is thought
to be crucial in GCC development as it allows embry-
onic germ cells to migrate, proliferate and survive (120).
It is important to recognize, that in patients with cryp-
torchidism or DSD, often delayedmaturation of the germ
cells occurs. In these patients the germ cells still express
POU5F1 after the age of 1 year, possibly leading to mis-
interpretation of germ cell maturation delay as GCNIS
and thus over-diagnosis. KITLG has been found to be
informative in distinguishing delayed mature germ cells
from GCNIS: the marker being positive in GCNIS/GB
cells and absent in germ cells having maturation delay
(Fig. 3) (111). This is of interest in the context of the
putative role of the KITLG P53 binding SNP in testicular
GCC development (see above). Also the distribution and
position within the seminiferous tubules of the germ cells
is helpful to differentiate between the two conditions
(121). Another important player in GCC development is
the aforementioned TSPY gene. The physiological role
of TSPY is not fully understood, but in normal testis it is
thought to control mitotic proliferation of the spermato-
gonia. TSPY overexpression in germ cells may therefore,
together with prolonged expression of POU5F1, result in
the survival and proliferation of germ cells in an unfavor-
able milieu. Strikingly, development of GB occurs only
in DSD patients with presence of the GBY region in their
karyotype. This region contains several genes, but TSPY
is the most likely candidate. In the fetal gonad TSPY is
expressed at a stable level, but it becomes more abundant
in GCNIS, GB and sometimes seminoma (122, 123).
In addition to the aberrant expression of genes and
transcription factors associated with pluripotency, which
are similar in malignant and normal fetal germ cells,
the epigenetic pattern of GCNIS is, like in PGCs, asso-
ciated with an open chromatin structure. GCNIS cells
show hypomethylation, as evidenced by immunohisto-
chemical staining, as does the invasive GCC component
seminoma (108, 109). Histone modification marks in
GCNIS indicate that these cells are arrested in a methyla-
tion state comparable to mouse PGCs between E7.5 and
E8.25 (124). It has been found that DPPA3 (STELLA),
a maternal effect gene expressed in testicular GCC and
PGCs, is hypomethylated in PGCs and testicular GCC,
indicating that expression in testicular GCC is linked to
a retained methylation status from the PGC progenitor
(125). Interestingly, analyses of 14 of the SNPs related
to testicular GCC identified in the GWAS in a cohort
of 52 postpubertal 46,XY DSD patients with androgen
insensitivity syndrome (AIS), showed that the SNPs near
KITLG (rs995030) and ATFZIP (rs2900333) distinguish
between patients with and without (pre-)GCNIS (101).
This implies that genetic susceptibility plays a role in
GCC at least in AIS, but possibly also in other forms
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of DSD. It remains to be clarified whether differences
exist dependent on the pathogenetic stage of the disease
regarding the impact of the SNPs.
Concluding remarks and relevant questions
for further investigation(s)
In summary, based on our interpretation of the cur-
rent data, the driving factor behind the development of
GCNIS or GB in individuals with a DSD is the inappro-
priate or defective microenvironment in which the germ
cells reside. The absence of a proper niche can result
in apoptosis, or an arrested development of the germ
cells, leading to infertility, or alternatively these cells can
subsequently give rise to the different precursor lesions.
Whether GCNIS or GB develops depends on the level
of testicularization of the gonad, as evidenced by the
expression of, respectively, SOX9 or FOXL2 in the sup-
porting cells. The expression of embryonic markers, and
epigenetics found in these precursor lesions ismost likely
not a causal mechanism, but a reflection of the devel-
opmental stage at which the cells are blocked. Whether
these precursors will develop later in life into a full blown
GCC likely depends on additional factors like a changed
endocrine milieu in a susceptible individual. This sus-
ceptibility might be conferred by the presence of the risk
SNPs identified in the different GWAS in men with a tes-
ticular GCC. In this respect, the finding that a specific
SNP in a p53 responsive element of KITLG can upregu-
late its expression is of particular interest. A remaining
question is if the identified SNPs also play a role in GCC
development/risk in DSD. And if so, whether they can
be used as a diagnostic tool in GCC risk stratification of
DSD patients, next to the existing parameters. To sum-
marize, a schematic representation of the pathobiology of
GCC inDSD is given in Fig. 4. To be able to answer these
questions and draw any meaningful conclusion, interna-
tional collaboration is necessary to reach a sufficient case
load of individuals with DSD in order to robustly analyze
the distribution of the risk SNPs.
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